

Thursday, 10. February 2022*Physicians Session*

14:00 - 14:15

A1

OP01 - Opening*Chair:* Nicolaus Kröger, DE*Chair:* John Gribben, GB*EBMT/EHA on-demand [Pre-recorded session]*

14:00 - 20:30

OD

YA01 - EBMT Trainee Committee & YoungEHA Ambassadors*Chair:* Claire Horgan, GB*Chair:* Eleni Gavriilaki, GR

YA-1	Science for the future: The basic science behind the cure <i>Speaker:</i> Michael Hudecek, DE	14:00 - 14:16
YA-2	What is real in the real world? A balanced walk through the data jungle: Current indications, trial Vs real world data, the importance of reporting <i>Speaker:</i> Anna Sureda, ES	14:16 - 14:31
YA-3	Infused, what now? How to learn to detect and treat adverse events: CRS & ICANS <i>Speaker:</i> Roberta Di Blasi, FR	14:31 - 14:53
YAQ	Closing remarks	14:53 - 14:57

Physicians Session

14:15 - 15:15

A1

PS01 - Session 1 - Clinical Indications*Chair:* Thomas Cluzeau, FR*Chair:* Claire Roddie, GB

PS01-1	Approved and emerging CAR-Ts in ALL <i>Speaker:</i> Mohamad Mohty, FR	14:15 - 14:27
PS01-2	Approved and Emerging CARTs in Non-Hodgkin's Lymphoma <i>Speaker:</i> Anna Sureda, ES	14:27 - 14:39
PS01-3	Emerging CAR-Ts in CLL <i>Speaker:</i> John Gribben, GB	14:39 - 14:51
PS01-4	Approved and emerging CAR-Ts in MM <i>Speaker:</i> Hermann Einsele, DE	14:51 - 15:03
PS01Q	Q&A	15:03 - 15:15

Physicians Session

15:25 - 16:25

A1

PS02 - Session 2 - New Clinical Data and Trial Pipeline*Chair:* Fabio Ciceri, IT*Chair:* Annette Künkele, DE

CD19 and GD2 CAR T in Pediatric Cancer	15:25 - 15:37
---	---------------

PS02-1	<i>Speaker:</i> Franco Locatelli, IT	
PS02-2	Factors associated with outcomes of CD19-targeted immunotherapy <i>Speaker:</i> Cameron Turtle, US	15:37 - 15:49
PS02-3	Update from 'HCB' CAR T trials <i>Speaker:</i> Julio Delgado, ES	15:49 - 16:01
PS02-4	Update from 'UKW' CAR T trials <i>Speaker:</i> Michael Hudecek, DE	16:01 - 16:13
PS02Q	Q&A	16:13 - 16:25

Best Abstracts

16:30 - 17:00

A1

BA01 - Best abstracts & Awards*Chair:* John Gribben, GB*Chair:* Nicolaus Kröger, DE

BA01-1	Discovery of Synthetic Cell States for Cancer Immunotherapy <i>Speaker:</i> Franziska Blaeschke, US	16:30 - 16:35
BA01-2	Microbial Short-chain Fatty Acids Enhance CAR T Cell-mediated Cancer Immunotherapy <i>Speaker:</i> Maik Luu, DE	16:35 - 16:40
BA01-3	Tumor-on-a-Chip for Efficacy and Safety Assessment of CAR-T Cell Therapy <i>Speaker:</i> Tengku Ibrahim Maulana, DE	16:40 - 16:45
BA01Q	Q&A	16:45 - 17:00

Break

17:00 - 17:30

A1

B1 - Break, Poster Viewing, Visit Exhibition*Keynote*

17:30 - 18:15

A1

KN01 - Keynote Lecture 1*Chair:* Sonia Guedan, ES*Chair:* Michael Loschi, FR

KN01-1	CAR T update and charting a way forward <i>Speaker:</i> Carl June, US	17:30 - 18:00
KN01Q	Q&A	18:00 - 18:15

Satellite Symposium

18:30 - 19:15

A1

SS01 - Satellite symposium by Janssen | Transforming the landscape of multiple myeloma with CAR T-cell therapies*Chair:* Philippe Moreau, FR

	Introduction	18:30 - 18:32
	<i>Speaker:</i> Philippe Moreau, FR	
SS01-2	How are CAR T-cell therapies changing the landscape in multiple myeloma?	18:32 - 18:47
	<i>Speaker:</i> Kwee Yong, GB	
SS02-3	Practical considerations for CAR T-cell therapy in patients with multiple myeloma	18:47 - 19:02
	<i>Speaker:</i> Inger Nijhof, NL	
	Panel discussion with Q&A	19:02 - 19:15
<i>Virtual Poster Tours</i>		
19:20 - 19:50		A1
PT01 - Virtual Poster Tour 1 Pre-clinical Data		
<i>Chair:</i> Michael Hudecek, DE		
PT01-1	Multi-antigen-Targeting of MM Using TCR and CAR Engineered T Cells	19:20 - 19:23
	<i>Oral Presenter:</i> Tassilo L A Wachsmann, NL	
PT01-2	Ribonucleoprotein-mediated CRISPR Prime Editing Enables Precision Editing in Primary T-cells	19:23 - 19:26
	<i>Oral Presenter:</i> Karl Petri, US	
PT01-3	CARAMBA	19:26 - 19:29
	<i>Oral Presenter:</i> Elisabeth Ehrend, DE	
PT01-4	CAR T-cells Targeting Aspergillus fumigatus	19:29 - 19:32
	<i>Oral Presenter:</i> Michelle Seif, DE	
PT01-5	Functional Activity of CIK Cells Plus Blinatumomab and CARCIK-CD19 Cells	19:32 - 19:35
	<i>Oral Presenter:</i> Silvia Zaninelli, IT	
PT01Q	Q&A	19:35 - 19:50
<i>Virtual Poster Tours</i>		
19:20 - 19:50		A2
PT02 - Virtual Poster Tour 2 Clinical data		
<i>Chair:</i> Ibrahim Yakoub-Agha, FR		
PT02-1	Superiority of Axicabtagene Ciloleucel in Second-line LBCL in the Elderly	19:20 - 19:23
	<i>Oral Presenter:</i> Tom van Meerten, NL	
PT02-2	Molecular CAR-T Cell Tracking in Real-world Patients with Severe ICANS	19:23 - 19:26
	<i>Oral Presenter:</i> Susanna Carolina Berger, DE	
PT02-3	CAR-HEMATOTOX: Risk-stratifying Infectious Complications and Disease Progression in r/r LBCL	19:26 - 19:29
	<i>Oral Presenter:</i> Kai Rejeski, DE	

PT02-4	Prophylactic Corticosteroids with Axi-Cel in R/R LBCL: ZUMA-1 Cohort 6 <i>Oral Presenter:</i> Olalekan O. Oluwole, US	19:29 - 19:32
PT02-5	Healthcare Decision-making in Patients with DLBCL: CAR-T vs non-CAR-T <i>Oral Presenter:</i> Lorna Warwick, CA	19:32 - 19:35
PT02Q	Q&A	19:35 - 19:50

Virtual Poster Tours
20:00 - 20:30

A1

PT03 - Virtual Poster Tour 3 | Pre-clinical Data

Chair: Michael Hudecek, DE

PT03-1	Multimodal Imaging of CAR T Cells in a Solid Tumor <i>Poster Presenter:</i> Rita Pfeifer, DE	20:00 - 20:03
PT03-2	PD-1/PD-L1 Axis in CAR-T Cell Function <i>Poster Presenter:</i> Irene Andreu-Saumell, ES	20:03 - 20:06
PT03-3	CXCR4-modified CD33.CAR-Clk with Enhanced Bone Marrow Homing in AML <i>Poster Presenter:</i> Marta Biondi, IT	20:06 - 20:09
PT03-4	Engineered T Cells Overcoming Rejection by Antibodies (CORA-T Cells) <i>Poster Presenter:</i> Anna Christina Dragon, DE	20:09 - 20:12
PT03-5	CAR-Tregs for Systemic Lupus Erythematosus <i>Oral Presenter:</i> Matteo Doglio, IT	20:12 - 20:15
PT03Q	Q&A	20:15 - 20:30

Virtual Poster Tours
20:00 - 20:30

A2

PT04 - Virtual Poster Tour 4 | Clinical Data

Chair: Ibrahim Yakoub-Agha, FR

PT04-1	Sleeping Beauty-engineered CARClk-CD19 in B-ALL Patients <i>Oral Presenter:</i> Chiara F. Magnani, CH	20:00 - 20:03
PT04-2	CD19 CAR-T Cells with HPK1 Knockout Might Be Safe and Effective for Adult r/r B-ALL <i>Oral Presenter:</i> Yu Wang, CN	20:03 - 20:06
PT04-3	CARTITUDE-2 Cohort A Update: Ciltacabtagene Autoleucel in Progressive, Multiple Myeloma <i>Oral Presenter:</i> Michel Delforge, BE	20:06 - 20:09
PT04-4	Locally Produced Novel BCMA CART Cells <i>Oral Presenter:</i> Nathalie Asherie, IL	20:09 - 20:12
PT04-5	Patient and Caregiver Experiences of CAR-T at a UK Centre <i>Oral Presenter:</i> Charlotte Stenson, GB	20:12 - 20:15

PT04Q

Q&A

20:15 - 20:30

Friday, 11. February 2022*Keynote*

09:00 - 09:45

A1

KN02 - Keynote Lecture 2*Chair:* Dirk Busch, DE*Chair:* Sara Mastaglio, ITKN02-1 **Strategies to increase tumor elimination with engineered T cells** 09:00 - 09:30*Speaker:* Stanley Riddell, USKN02Q **Q&A** 09:30 - 09:45*Nurses Session*

09:00 - 09:10

A2

OPN1 - Introduction & Welcome*Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CH*Nurses Session*

09:10 - 09:40

A2

NG00 - The Nice Experience*Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CHNG00-1 **Introducing the CART programme into practice – the Nice experience** 09:10 - 09:30*Speaker:* Alizee Soldati, FRNG00Q **Q&A** 09:30 - 09:40*Nurses Session*

09:45 - 10:50

A2

NG01 - Nurses Session I - Overview*Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CHNG01-1 **Overview of immune system and its role in fighting cancer** 09:45 - 10:03*Speaker:* Antonia Mueller, CHNG01-2 **Overview of clinical studies in haematological malignancies** 10:03 - 10:21*Speaker:* Adrian Bloor, GBNG01-3 **Paediatric indications and experience** 10:21 - 10:39*Speaker:* Daphna Hutt, ILNG01Q **Q&A** 10:39 - 10:50

Physicians Session

09:50 - 10:50

A1

PS03 - Session 3 - Next-Gen CAR-T Therapy*Chair:* Álvaro Urbano Ispizua, ES*Chair:* Chiara Bonini, IT

PS03-1	Engineering Next-Generation CAR-T Cells for Cancer Therapy <i>Speaker:</i> Yvonne Chen, US	09:50 - 10:02
PS03-2	In vivo CAR T cell generation <i>Speaker:</i> Christian Buchholz, DE	10:02 - 10:14
PS03-3	iPSC-derived CAR-T cells: the road to clinical translation <i>Speaker:</i> Maria Themeli, NL	10:14 - 10:26
PS03-4	CAR-T therapy and the microbiome <i>Speaker:</i> Christoph Stein-Thöringer, DE	10:26 - 10:38
PS03Q	Q&A	10:38 - 10:50

Break

10:50 - 11:25

A1

B2 - Break, Poster Viewing, Visit Exhibition*Industry Theatre*

10:50 - 11:20

A1

IT02 - Industry Theatre (Auditorium 1): The Future of CART | by Novartis

IT02-1	Advancing Manufacturing process in CART <i>Speaker:</i> Bernd Eschgfäller, CH	10:50 - 11:00
IT02-2	The Next Generation of CART <i>Speaker:</i> Aby Buchbinder, US	11:00 - 11:10
IT02-3	Interactive Q&A discussion	11:10 - 11:20

Nurses Session

11:20 - 13:05

A2

NG02 - Nurses Session II - Treatment Updates*Chair:* John Murray, GB*Chair:* Ruth Clout, GB

NG02-2	CART in lymphoma <i>Speaker:</i> Ulrich Jäger, AT	11:20 - 11:45
NG02-1	CART in myeloma <i>Speaker:</i> Maaïke de Ruijter, NL	11:45 - 12:05
NG02-3	Off the shelf/Allo CART <i>Speaker:</i> Jürgen Kuball, NL	12:05 - 12:25
NG02-4	CART, IEC, BITE – what does the new technology mean for patients with solid malignancies <i>Speaker:</i> Fiona Thistlethwaite, GB	12:25 - 12:45

Speaker: Dick Sundh, AU

Satellite Symposium

13:45 - 14:30

A1

SS02 - Satellite symposium by Bristol Myers Squibb | CAR T cell therapy: current status and new perspectives

Chair: Pere Barba, ES

SS02-1	Welcome and Introduction	13:45 - 13:50
SS02-2	From innovation to implementation: CAR T for r/r LBCL <i>Speaker:</i> Stephan Mielke, SE	13:50 - 14:05
SS02-3	The future of cellular therapy in MM <i>Speaker:</i> Salomon Manier, FR	14:05 - 14:20
SS02Q	Q&A and discussion All faculty, moderated by Pere Barba Closing remarks	14:20 - 14:30

Nurses Session

14:30 - 16:00

A2

NG03 - Nurses Session III - Patient Experience

Chair: Ruth Clout, GB

Chair: John Murray, GB

NG03-1	Patient experience - interview <i>Speaker:</i> Guy Bouguet, FR <i>Speaker:</i> Philippe Piedigrossi, IT	14:30 - 14:55
NG03-2	The role of charities in patient care <i>Speaker:</i> Kristina Modic, SI	14:55 - 15:07
NG03-3	Working with the third sector to enhance patient care <i>Speaker:</i> Andreas L.G. Reimann, DE	15:07 - 15:20
NG03-4	What supportive care do patients need? <i>Speaker:</i> Natacha Bolaños, ES	15:20 - 15:45
NG03Q	Q&A	15:45 - 16:00

Physicians Session

14:35 - 15:35

A1

PS05 - Session 5 - Interactive pros / cons

Chair: Jürgen Kuball, NL

Chair: Martina Schuessler-Lenz, DE

Chair: Attilio Bondanza, GB

PS05-1	Allo vs. Auto CAR-T: Auto <i>Speaker:</i> Michael Schmitt, DE	14:35 - 14:40
PS05-2	Allo vs. Auto CAR-T: Allo <i>Speaker:</i> Reuben Benjamin, GB	14:40 - 14:45
PS05Q1	Debate	14:45 - 15:05

PS05-3	What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing pro POC <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	15:05 - 15:10
PS05-4	What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing pro CIM <i>Speaker:</i> Ulrike Köhl, DE	15:10 - 15:15
PS05Q2	Debate	15:15 - 15:35

Physicians Session
15:40 - 16:40

A1

PS06 - Session 6 - New CAR-T Indications

Chair: Michael Hudecek, DE

Chair: Raffaella Greco, IT

PS06-1	In vivo CART therapy for fibrosis <i>Speaker:</i> Jonathan Epstein, US	15:40 - 15:52
PS06-2	CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus <i>Speaker:</i> Andreas Mackensen, DE	15:52 - 16:04
PS06-3	Opportunities and challenges of immunotherapeutic approaches of HBV cure <i>Speaker:</i> Ulrike Protzer, DE	16:04 - 16:16
PS06-4	Engineering Specific T cells to Modulate Adverse Immune Responses: Driving CARs to BARs <i>Speaker:</i> David Scott, US	16:16 - 16:28
PS06Q	Q&A	16:28 - 16:40

Break
16:00 - 16:30

A2

NB - Break, Poster Viewing, Visit Exhibition

Nurses Session
16:30 - 17:50

A2

NG04 - Nurses Session IV - Treatment outcome influencers

Chair: Erik Aerts, CH

Chair: Michelle Kenyon, GB

NG04-1	'Prehab to rehab' – optimising health and wellbeing <i>Speaker:</i> Aimee Green, GB	16:30 - 16:50
NG04-2	Training and education – how to fill the gaps by working together <i>Speaker:</i> Julia Ruiz Pato, ES	16:50 - 17:10
NG04-3	Late effects – expected and unexpected <i>Speaker:</i> Patrick Hayden, IE	17:10 - 17:30
NG04-4	Case study	17:30 - 17:45

	<i>Speaker: Daniela Beyer-Bontognali, CH</i>	
NG04Q	Q&A	17:45 - 17:50
<i>Break</i>		
	16:40 - 17:00	A1
B4 - Break, Poster Viewing, Visit Exhibition		
<i>Physicians Session</i>		
	17:00 - 17:45	A1
PS07 - Session 7 - CAR-T: New Standard of Care in Lymphoma?		
<i>Chair: Christian Chabannon, FR</i>		
<i>Chair: Marie Jose Kersten, NL</i>		
PS07-1	Second line treatment in aggressive B-NHL: CAR-T or autologous transplant?	17:00 - 17:15
	<i>Speaker: Mehdi Hamadani, US</i>	
PS07-2	Round table	17:15 - 17:45
	<i>Speaker: Ulrich Jäger, AT</i>	
	<i>Speaker: Bertram Glass, DE</i>	
	<i>Speaker: Guy Bouguet, FR</i>	
	<i>Speaker: Anna Sureda, ES</i>	
<i>Keynote</i>		
	17:50 - 19:10	A1
KN03 - Panel Chairs & Keynote Lecture 3		
<i>Chair: Ibrahim Yakoub-Agha, FR</i>		
<i>Chair: Michael Hudecek, DE</i>		
<i>Chair: Maria Themeli, NL</i>		
<i>Chair: Hermann Einsele, DE</i>		
KN03-all	Where do we stand and where do we go with CAR-T? Discussion	17:50 - 18:20
	<i>Speaker: Michel Sadelain, US</i>	
KN03-1	Antigen sensitivity of CAR T cells	18:20 - 18:50
	<i>Speaker: Michel Sadelain, US</i>	
KN03Q	Q&A	18:50 - 19:10
<i>Nurses Session</i>		
	17:55 - 18:05	A2
NGCL - Closing remarks		
<i>Chair: Erik Aerts, CH</i>		
<i>Chair: Michelle Kenyon, GB</i>		
<i>Physicians Session</i>		
	19:15 - 20:15	A1
PA01 - Things you need to know about CAR T-cell therapy: talking about CAR-T cell therapy in lay language Roundtable		
<i>Chair: Natacha Bolaños, ES</i>		

PA01-1	Clinician Perspective <i>Speaker:</i> Marie Jose Kersten, NL <i>Speaker:</i> Yavor Pertov, BG	19:15 - 19:15
PA01-2	Patient perspective <i>Speaker:</i> Jonathan Clark, GB	19:15 - 19:15
PA01-3	Nurse Perspective <i>Speaker:</i> Mairéad Ní Chonghaile, IE	19:15 - 19:15
PA01-4	Psychologist Perspective <i>Speaker:</i> Surabhi Chaturvedi, GB	19:15 - 19:15

Saturday, 12. February 2022*Physicians Session*

08:30 - 09:45

A1

PS08 - Session 08 - Clinical management*Chair:* Marion Subklewe, DE*Chair:* Hans Scheurer, NL

PS08-1	MAS/ICANS - CRS <i>Speaker:</i> Claire Roddie, GB	08:30 - 08:47
PS08-2	Cytopenia/Infections <i>Speaker:</i> Max Topp, DE	08:47 - 09:04
PS08-3	COVID-19 and CAR-T Therapy <i>Speaker:</i> Arnon Nagler, IL	09:04 - 09:21
PS08-4	Specific organ tox (Cardiac) <i>Speaker:</i> Daniel Chen, GB	09:21 - 09:33
PS08Q	Q&A	09:33 - 09:45

Physicians Session

08:30 - 09:45

A2

PS09 - Session 09 - CAR T Technology Forum*Chair:* Javier Briones, ES*Chair:* Miriam Alb, DE

PS09-1	Gene transfer and genomic safety <i>Speaker:</i> Zoltán Ivics, DE	08:30 - 08:42
PS09-2	Safety & Efficacy Models for CAR-T <i>Speaker:</i> Monica Casucci, IT	08:42 - 08:54
PS09-3	Machine learning in single cell genomics <i>Speaker:</i> Fabian Theis, DE	08:54 - 09:06
PS09-4	T cell subset selection for CAR engineering <i>Speaker:</i> Luca Gattinoni, DE	09:06 - 09:18
PS09D	Debate	09:18 - 09:45

Satellite Symposium

09:45 - 10:30

A1

SS04 - Satellite Symposium by Gilead Kite on R/R DLBCL highlights in CAR T from ASH 2021, Implications for current 3L+ practice

SS04-1	Introduction to the symposium	09:45 - 09:47
SS04-2	What have we learned about the pivotal CAR T trials? <i>Speaker:</i> Tanya Siddiqi, US	09:47 - 09:56
SS04-3	What learnings are there in the real-world use of CAR T? <i>Speaker:</i> Roch Houot, FR	09:56 - 10:09

SS04-4	What were the other DLBCL highlights in CAR T from ASH? <i>Speaker:</i> Sridhar Chaganti, GB	10:09 - 10:20
SS04Q	Close	10:20 - 10:23
<i>Break</i>		
10:30 - 11:00		
B5 - Break, Poster Viewing, Visit Exhibition		
<i>Physicians Session</i>		
11:00 - 12:15		
PS10 - Session 10 - How to set-up and run a CAR-T unit		
<i>Chair:</i> Ibrahim Yakoub-Agha, FR		
<i>Chair:</i> Natacha Bolaños, ES		
PS10-1	How to set-up and run a CAR-T unit <i>Speaker:</i> Fabio Ciceri, IT	11:00 - 11:15
PS10-2	Patient communication <i>Speaker:</i> Marie Jose Kersten, NL	11:15 - 11:30
PS10-3	Academic production <i>Speaker:</i> Halvard Bönig, DE	11:30 - 11:45
PS10-4	Patient perspective <i>Speaker:</i> Lorna Warwick, CA	11:45 - 12:00
PS10Q	Q&A	12:00 - 12:15
<i>Physicians Session</i>		
11:00 - 12:15		
PS11 - Session 11 - Biotech Forum		
<i>Chair:</i> Ulf Grawunder, CH		
<i>Chair:</i> Michael Hudecek, DE		
PS11-1	The Inventor's Perspective: Delivering CAR-Ts to the market <i>Speaker:</i> Ulf Grawunder, CH	11:00 - 11:15
PS11-2	The Analysts' Perspective: The CAR-T Market by 2030 <i>Speaker:</i> Pemba Lahmo, IN <i>Speaker:</i> Rupali Chaudhary, IN	11:15 - 11:30
PS11-3	Biotech showcase <i>Speaker:</i> Armin Ehninger, DE <i>Speaker:</i> David Gilham, US <i>Speaker:</i> Ulf Grawunder, CH <i>Speaker:</i> Elisa Kieback, DE <i>Speaker:</i> Michael O'Dwyer, IE	11:30 - 12:00
PS11Q	Q&A	12:00 - 12:15

Best Abstracts

12:20 - 13:35

A1

BA03 - Best abstracts flash talks*Chair:* Hermann Einsele, DE*Chair:* Maria Themeli, NL

BA03-1	N-glycosylation Inhibition Reverts Immunosuppression by TME Cells <i>Speaker:</i> Camilla Sirini, IT	12:20 - 12:25
BA03-2	Gene-transfer Methodology and Target-antigen Density Determine Car T-cell Performance <i>Speaker:</i> Leon Gehrke, DE	12:25 - 12:30
BA03-3	Dual CAR-CIK Cells for the Targeting of AML <i>Speaker:</i> Sarah Tettamanti, IT	12:30 - 12:35
BA03-4	Characterization of Antigen-driven CAR-T Cell Dysfunction in a Mouse Model of Her2-positive Solid Tumors <i>Speaker:</i> Paula Barbao, ES	12:35 - 12:40
BA03-5	Anti-CD117 CAR T Cells for Acute Myeloid Leukemia <i>Speaker:</i> Chiara F. Magnani, CH	12:40 - 12:45
BA03-6	ARI-0001 CART19 Cells in Relapsed/Refractory CLL and Richter's Transformation <i>Speaker:</i> Valentin Ortiz-Maldonado, ES	12:45 - 12:50
BA03-7	AML Targeting via UniCAR T-cells <i>Speaker:</i> Laura Volta, CH	12:50 - 12:55
BA03Q	Q&A	12:55 - 13:35

Physicians Session

12:20 - 13:35

A2

PS12 - Session 12 - Trial management*Chair:* Stephan Mielke, SE*Chair:* Annalisa Ruggeri, IT

PS12-1	European trial landscape <i>Speaker:</i> Álvaro Urbano Ispizua, ES	12:20 - 12:32
PS12-2	Multinational trial experience <i>Speaker:</i> Julia Beckmann, DE	12:32 - 12:44
PS12-3	Standardization in CAR-T trials <i>Speaker:</i> H�el�ene Negre, FR	12:44 - 12:56
PS12-4	EBMT CAR-T Data base <i>Speaker:</i> Christian Chabannon, FR	12:56 - 13:08
PS12-5	EBMT & EHA GoCART Initiative <i>Speaker:</i> J�urgen Kuball, NL	13:08 - 13:20
PS12D	Debate	13:20 - 13:35

Keynote

13:45 - 14:30

A1

KN04 - Keynote Lecture 4*Chair:* Anna Sureda, ES*Chair:* Elizabeth Macintyre, FRKN04-1 **CAR T Cells for Diffuse Midline Gliomas and Other Pediatric** 13:45 - 14:15
Solid Tumors*Speaker:* Crystal Mackall, USKN04Q **Q&A** 14:15 - 14:30*Speaker:* Michael Hudecek, DE*Speaker:* Ibrahim Yakoub-Agha, FR*Physicians Session*

14:30 - 14:45

A1

CLS - Closing remarks*Chair:* Ibrahim Yakoub-Agha, FR*Chair:* Michael Hudecek, DE